- Neutral OutlookNo opinion of CEO
I worked at Conceptus full-time (More than 5 years)
Exciting start-up culture in growth mode. Even as economy faltered, impacting elective procedures, management did their best to invest in the sales force.
Purchased by Bayer in 2013, significantly changing leadership and culture. Prior to that, political power structure was shifting to more cut-throat survival mode with inside executives.
Advice to Management
Nothing applicable after company was purchased. This is not a device company as much as a pharmaceutical company in scope and execution.
Let us know if we're missing any workplace or industry recognition –
Conceptus, despite the sound of its name, works to prevent conception, not help it along. The company develops, makes, and markets women's health care products, namely a minimally invasive permanent birth control procedure called Essure. Soft, flexible micro-insert devices are placed in the fallopian tubes without incisions, allowing tissue to grow over them as a barrier for the egg. Essure does not contain hormones and is designed to become effective after three months. Conceptus markets Essure primarily to gynecologists in the US through a direct sales force and ...